Cite
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
MLA
Zhou, Qing, et al. “Sugemalimab versus Placebo after Concurrent or Sequential Chemoradiotherapy in Patients with Locally Advanced, Unresectable, Stage III Non-Small-Cell Lung Cancer in China (GEMSTONE-301): Interim Results of a Randomised, Double-Blind, Multicentre, Phase 3 Trial.” Lancet Oncology, vol. 23, no. 2, Feb. 2022, pp. 209–19. EBSCOhost, https://doi.org/10.1016/S1470-2045(21)00630-6.
APA
Zhou, Q., Chen, M., Jiang, O., Pan, Y., Hu, D., Lin, Q., Wu, G., Cui, J., Chang, J., Cheng, Y., Huang, C., Liu, A., Yang, N., Gong, Y., Zhu, C., Ma, Z., Fang, J., Chen, G., Zhao, J., & Shi, A. (2022). Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, 23(2), 209–219. https://doi.org/10.1016/S1470-2045(21)00630-6
Chicago
Zhou, Qing, Ming Chen, Ou Jiang, Yi Pan, Desheng Hu, Qin Lin, Gang Wu, et al. 2022. “Sugemalimab versus Placebo after Concurrent or Sequential Chemoradiotherapy in Patients with Locally Advanced, Unresectable, Stage III Non-Small-Cell Lung Cancer in China (GEMSTONE-301): Interim Results of a Randomised, Double-Blind, Multicentre, Phase 3 Trial.” Lancet Oncology 23 (2): 209–19. doi:10.1016/S1470-2045(21)00630-6.